oprelvekin

[o-prel´vĕ-kin″]

recombinant interleukin-11, used as a stimulator of hematopoiesis to prevent thrombocytopenia following myelosuppressive chemotherapy.

IL11

A gene on chromosome 19q13.3-q13.4 that encodes interleukin-11, a member of the gp130 family of cytokines, which drive the assembly of multi-subunit receptor complexes, all of which contain at least one molecule of the transmembrane signalling receptor IL6ST. IL11 directly stimulates the proliferation of haematopoietic stem cells and megakaryocyte progenitor cells, and it induces megakaryocyte maturation resulting in increased platelet production.

References in periodicals archive

At present, the US Food and Drug Administration has approved recombinant interleukin (IL)-11 (oprelvekin) for thrombocytopenia induced by chemotherapeutic agents.

[25,26] Recombinant human IL-11 (oprelvekin) is known to cause fluid retention with dilutional anemia, peripheral edema, pleural effusions, papilledema, and atrial arrhythmias which is severe and life-threatening in nature.

The major hurdle with the use of thrombopoietin agonist and oprelvekin was cost, romiplostim ($1400), eltrombopag ($2000), and oprelvekin ($2366) for the management of CIT per week, respectively.

Effect of Carica papaya leaf extract on platelet count in chemotherapy-induced thrombocytopenic patients: a preliminary study

Periostitis secondary to interleukin -11 (Oprelvekin, Neumega).

Generalized weakness and fatigue

Oprelvekin (Neumega[R]), also known as interleukin 11, is a growth factor that is used to prevent thrombocytopenia following chemotherapy infusion.

Essential oncology facts for the float nurse:

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.